Monday, 22 July 2019

Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)